{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T09:26:21Z","timestamp":1649064381353},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TCRM"],"DOI":"10.2147\/tcrm.s5855","type":"journal-article","created":{"date-parts":[[2010,12,23]],"date-time":"2010-12-23T01:51:21Z","timestamp":1293069081000},"page":"1","source":"Crossref","is-referenced-by-count":2,"title":["Role of rituximab in first-line treatment of chronic lymphocytic leukemia"],"prefix":"10.2147","author":[{"given":"Gautam","family":"Borthakur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Bryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2010,12]]},"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=8460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T21:58:14Z","timestamp":1477864694000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dovepress.com\/role-of-rituximab-in-first-line-treatment-of-chronic-lymphocytic-leuke-peer-reviewed-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/tcrm.s5855","relation":{},"ISSN":["1178-203X"],"issn-type":[{"value":"1178-203X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}